Onward Medical announced today that it enrolled the first participant in Empower BP, a global pivotal study assessing its ARC ...

At the recently concluded North American Neuromodulation Society annual meeting, Boston presented a total of 17 abstracts.

Abbott has touted the potential of its neuromodulation portfolio in reducing patient and healthcare burdens associated with ...

Abbott Park, Illinois Tuesday, January 27, 2026, 13:00 Hrs [IST] ...

Abbott ABT recently announced the first usage of its Eterna spinal cord stimulator (SCS) system in Canada. This marks a significant milestone in the company’s approach to chronic pain management. The ...

LAS VEGAS, Nev.--(BUSINESS WIRE)--During the scientific sessions at the 16 th Annual NANS Conference, Dr. Liong Liem, Anesthesiologist at Sint Antonius Ziekenhuis in the Netherlands and member of the ...

Protégé upgradeable neurostimulator from St. Jude Medical is the world’s smallest, longest-lasting rechargeable device to treat chronic pain SCS system is designed to be non-invasively upgraded to ...

Boston Scientific, Inc. BSX recently received FDA approval for an expanded indication of the WaveWriter Alpha Spinal Cord Stimulator (“SCS”) Systems. With this approval, the system will be available ...

Abbott Laboratories (NYSE:ABT) announced Thursday that the FDA approved expanded MRI labeling for its pain relief device Eterna spinal cord stimulation (SCS) system, allowing its use in patients who ...

Introduction: Spinal cord stimulation (SCS) is a well-established and accepted treatment for chronic neuropathic, nociplastic (neuropathic-like) and ischemic pain. The heterogeneity of patients in ...